SecBot SecBot

COEP

Z Squared Inc.
Nasdaq· Finance Services· Inc. DE· CIK 0001759186 Biotech & Drug Discovery
Former ticker of Z Squared Inc. · ZSQR stock page →
—
Insider net
$0
no open-market trades · 12 mo
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 mixed oldest → newest, height = score
Avg score ·High conf. 1/1
Strongest MIXED Coeptis Therapeutics announced that Nasdaq has approved the listing of the post-merger company's common…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

The Street

last action Sep 2023
Recent actions
DateFirmActionRating
Sep 22, 2023Ladenburg Thalmann
INITIATE
INITIATEBuy
May 18, 2023EF Hutton
REITERATE
REITERATEBuy
May 10, 2023EF Hutton
REITERATE
REITERATEBuy
Apr 19, 2023JonesTrading
INITIATE
INITIATEBuy
Apr 5, 2023EF Hutton
REITERATE
REITERATEBuy
Mar 29, 2023EF Hutton
REITERATE
REITERATEBuy
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Apr 27, 2026
Short interest
FTD: COEP — 33,426 shares ($0.5M) failed to deliver
Settlement: 20260427, Price: $16.40, FTD Value: $548,186.4, COEPTIS THERAPEUTICS HLDGS INC
Apr 7, 2026
M&A
Coeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing Application
~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~
Mar 25, 2026
Earnings date
COEP Q4 2025 Earnings After Market Close — 2026-03-25

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Feb 11, 2026
Deschamps Philippe
Director
AWARD3,250 sh
Feb 11, 2026
Yerace Daniel Alexander
VP Operations
EXERCISE$104.1K
Feb 11, 2026
Yerace Daniel Alexander
VP Operations
AWARD20,000 sh
Feb 11, 2026
Calise Chris
Director
EXERCISE$60.2K
Feb 11, 2026
Mehalick David
CEO and President
EXERCISE$1.0M
Feb 11, 2026
Mehalick David
CEO and President
AWARD51,250 sh
Feb 11, 2026
Cochran Christopher P.
Director
AWARD3,250 sh
Feb 11, 2026
Salkind Gene
Director
EXERCISE$60.2K

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Next Q———$0.00
Current FY———$0.00
Current Q———$0.00
Next FY———$0.00
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Apr 27, 2026 Short interest
FTD: COEP — 33,426 shares ($0.5M) failed to deliver
Settlement: 20260427, Price: $16.40, FTD Value: $548,186.4, COEPTIS THERAPEUTICS HLDGS INC
Apr 7, 2026 Press
Coeptis Therapeutics announced that Nasdaq has approved the listing of the post-merger company's common stock under…
Impact 6/10
Feb 11, 2026 Insider
Deschamps Philippe was granted 3,250 shares
Director
Feb 11, 2026 Insider
Yerace Daniel Alexander acquired via exercise 10,000 shares
VP Operations @ $10.41 ($104.1K)
Feb 11, 2026 Insider
Yerace Daniel Alexander was granted 20,000 shares
VP Operations

SecBot reports

All COEP filing & press-release reports (1)